3871
Naphthol AS-BI Phosphoric Acid Solution
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
form
solution
Quality Level
shelf life
Expiry date on the label.
IVD
for in vitro diagnostic use
concentration
12.5 mg/mL
application(s)
hematology
histology
shipped in
wet ice
storage temp.
2-8°C
SMILES string
COc1ccccc1NC(=O)c2cc3cc(Br)ccc3cc2OP(O)(O)=O
InChI
1S/C18H15BrNO6P/c1-25-16-5-3-2-4-15(16)20-18(21)14-9-12-8-13(19)7-6-11(12)10-17(14)26-27(22,23)24/h2-10H,1H3,(H,20,21)(H2,22,23,24)
InChI key
HUXIAXQSTATULQ-UHFFFAOYSA-N
Application
For use in the Sigma Acid Phosphatase (TRAP) Procedure, Kit 387A
Other Notes
Napthol AS-BI phosphoric acid, 12.5 mg/mL.
Still not finding the right product?
Explore all of our products under Naphthol AS-BI Phosphoric Acid Solution
Storage Class
12 - Non Combustible Liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Veronika Kozlova et al.
PloS one, 15(3), e0229170-e0229170 (2020-03-27)
Surface protein CD20 serves as the critical target of immunotherapy in various B-cell malignancies for decades, however its biological function and regulation remain largely elusive. Better understanding of CD20 function may help to design improved rational therapies to prevent development
Yi-Ju Pan et al.
Inflammation research : official journal of the European Histamine Research Society ... [et al.], 67(10), 847-861 (2018-08-16)
To investigate the amelioration effects of quetiapine on rheumatoid arthritis with RAW 264.7 macrophage and collagen-induced arthritis (CIA) DBA/1J mouse model. RAW 264.7 macrophage and DBA/1J mice. Lipopolysaccharide and collagen. RAW 264.7 macrophages stimulated by lipopolysaccharide (LPS) followed by quetiapine
Daniel P Duarte et al.
Nature communications, 11(1), 2319-2319 (2020-05-10)
Bruton's tyrosine kinase (Btk) is critical for B-cell maturation and activation. Btk loss-of-function mutations cause human X-linked agammaglobulinemia (XLA). In contrast, Btk signaling sustains growth of several B-cell neoplasms which may be treated with tyrosine kinase inhibitors (TKIs). Here, we